慢性肾脏病患者戒烟与动脉粥样硬化性心血管事件和死亡率。

IF 4.8 2区 医学 Q1 TRANSPLANTATION Nephrology Dialysis Transplantation Pub Date : 2024-11-15 DOI:10.1093/ndt/gfae268
Young Su Joo, Hae-Ryoung Yun, Hyung Woo Kim, Hee Byung Koh, Chan-Young Jung, Tae-Ik Chang, Jung Tak Park, Sue Kyung Park, Young Youl Hyun, Yeong Hoon Kim, Suah Sung, Tae-Hyun Yoo, Kook-Hwan Oh, Shin-Wook Kang, Seung Hyeok Han
{"title":"慢性肾脏病患者戒烟与动脉粥样硬化性心血管事件和死亡率。","authors":"Young Su Joo, Hae-Ryoung Yun, Hyung Woo Kim, Hee Byung Koh, Chan-Young Jung, Tae-Ik Chang, Jung Tak Park, Sue Kyung Park, Young Youl Hyun, Yeong Hoon Kim, Suah Sung, Tae-Hyun Yoo, Kook-Hwan Oh, Shin-Wook Kang, Seung Hyeok Han","doi":"10.1093/ndt/gfae268","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Smoking cessation is recommended to reduce excess atherosclerotic cardiovascular disease (ASCVD) and mortality in patients with chronic kidney disease (CKD). However, this recommendation is largely based on observational studies on the general population Therefore, we aimed to evaluate the association of smoking dose and smoking cessation duration with ASCVD and mortality in patients with CKD.</p><p><strong>Methods: </strong>We compiled a comprehensive pooled dataset comprising 66 245 participants with CKD from the KNOW-CKD and the UK Biobank cohort. Additionally, we included 307 353 participants without CKD from the UK Biobank cohort. Participants were categorized according to smoking dose and duration of smoking cessation base on a questionnaire. The primary outcome was a composite of ASCVD events or all-cause mortality.</p><p><strong>Results: </strong>Over a median follow-up period of 13.2 years, 14 671 (22.1%) participants reached the primary outcome. In the pooled CKD cohort, compared to never smokers, former and current smokers exhibited a 1.30- and 2.14-fold higher risk of the primary outcome, respectively. Among former smokers, the hazard ratios (HRs) (95% confidence intervals [CIs]) for smoking loads < 20 and ≥ 20 pack-years were 1.05 (1.00-1.10) and 2.14 (2.05-2.25), respectively. The increased risk of the primary outcome was attenuated by longer smoking cessation. The HRs (95% CIs) for smoking cessation of < 10 years, 10-20 years, and ≥ 20 years were 1.75 (1.65-1.86), 1.43 (1.34-1.52), and 1.11 (1.06-1.16), respectively, compared with never smokers. This association was also observed in individuals without CKD, but the risk was comparable between former smokers with smoking cessation ≥ 20 years and non-smokers, suggesting that a longer cessation is required in patients with CKD to offset the smoking-related adverse effects.</p><p><strong>Conclusions: </strong>Among former smokers with CKD, the risk of ASCVD or mortality was substantially attenuated with less smoking load and a longer duration of smoking cessation.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease.\",\"authors\":\"Young Su Joo, Hae-Ryoung Yun, Hyung Woo Kim, Hee Byung Koh, Chan-Young Jung, Tae-Ik Chang, Jung Tak Park, Sue Kyung Park, Young Youl Hyun, Yeong Hoon Kim, Suah Sung, Tae-Hyun Yoo, Kook-Hwan Oh, Shin-Wook Kang, Seung Hyeok Han\",\"doi\":\"10.1093/ndt/gfae268\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Smoking cessation is recommended to reduce excess atherosclerotic cardiovascular disease (ASCVD) and mortality in patients with chronic kidney disease (CKD). However, this recommendation is largely based on observational studies on the general population Therefore, we aimed to evaluate the association of smoking dose and smoking cessation duration with ASCVD and mortality in patients with CKD.</p><p><strong>Methods: </strong>We compiled a comprehensive pooled dataset comprising 66 245 participants with CKD from the KNOW-CKD and the UK Biobank cohort. Additionally, we included 307 353 participants without CKD from the UK Biobank cohort. Participants were categorized according to smoking dose and duration of smoking cessation base on a questionnaire. The primary outcome was a composite of ASCVD events or all-cause mortality.</p><p><strong>Results: </strong>Over a median follow-up period of 13.2 years, 14 671 (22.1%) participants reached the primary outcome. In the pooled CKD cohort, compared to never smokers, former and current smokers exhibited a 1.30- and 2.14-fold higher risk of the primary outcome, respectively. Among former smokers, the hazard ratios (HRs) (95% confidence intervals [CIs]) for smoking loads < 20 and ≥ 20 pack-years were 1.05 (1.00-1.10) and 2.14 (2.05-2.25), respectively. The increased risk of the primary outcome was attenuated by longer smoking cessation. The HRs (95% CIs) for smoking cessation of < 10 years, 10-20 years, and ≥ 20 years were 1.75 (1.65-1.86), 1.43 (1.34-1.52), and 1.11 (1.06-1.16), respectively, compared with never smokers. This association was also observed in individuals without CKD, but the risk was comparable between former smokers with smoking cessation ≥ 20 years and non-smokers, suggesting that a longer cessation is required in patients with CKD to offset the smoking-related adverse effects.</p><p><strong>Conclusions: </strong>Among former smokers with CKD, the risk of ASCVD or mortality was substantially attenuated with less smoking load and a longer duration of smoking cessation.</p>\",\"PeriodicalId\":19078,\"journal\":{\"name\":\"Nephrology Dialysis Transplantation\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrology Dialysis Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ndt/gfae268\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"TRANSPLANTATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology Dialysis Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ndt/gfae268","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

摘要

背景:建议慢性肾脏病(CKD)患者戒烟以减少动脉粥样硬化性心血管疾病(ASCVD)和死亡率。因此,我们旨在评估吸烟剂量和戒烟持续时间与 CKD 患者 ASCVD 和死亡率的关系:我们从 KNOW-CKD 和英国生物库队列中收集了 66 245 名 CKD 患者的综合数据集。此外,我们还纳入了英国生物库队列中 307 353 名未患 CKD 的参与者。根据调查问卷对参与者的吸烟剂量和戒烟时间进行分类。主要结果是ASCVD事件或全因死亡率的复合结果:中位随访期为13.2年,14 671人(22.1%)达到了主要结局。在汇总的 CKD 队列中,与从不吸烟者相比,曾经吸烟者和目前吸烟者发生主要结局的风险分别高出 1.30 倍和 2.14 倍。在曾经吸烟者中,吸烟负荷的危险比(HRs)(95% 置信区间[CIs])为 1.5 倍:在患有慢性肾脏病的前吸烟者中,吸烟量越少、戒烟时间越长,发生 ASCVD 或死亡的风险就越低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease.

Background: Smoking cessation is recommended to reduce excess atherosclerotic cardiovascular disease (ASCVD) and mortality in patients with chronic kidney disease (CKD). However, this recommendation is largely based on observational studies on the general population Therefore, we aimed to evaluate the association of smoking dose and smoking cessation duration with ASCVD and mortality in patients with CKD.

Methods: We compiled a comprehensive pooled dataset comprising 66 245 participants with CKD from the KNOW-CKD and the UK Biobank cohort. Additionally, we included 307 353 participants without CKD from the UK Biobank cohort. Participants were categorized according to smoking dose and duration of smoking cessation base on a questionnaire. The primary outcome was a composite of ASCVD events or all-cause mortality.

Results: Over a median follow-up period of 13.2 years, 14 671 (22.1%) participants reached the primary outcome. In the pooled CKD cohort, compared to never smokers, former and current smokers exhibited a 1.30- and 2.14-fold higher risk of the primary outcome, respectively. Among former smokers, the hazard ratios (HRs) (95% confidence intervals [CIs]) for smoking loads < 20 and ≥ 20 pack-years were 1.05 (1.00-1.10) and 2.14 (2.05-2.25), respectively. The increased risk of the primary outcome was attenuated by longer smoking cessation. The HRs (95% CIs) for smoking cessation of < 10 years, 10-20 years, and ≥ 20 years were 1.75 (1.65-1.86), 1.43 (1.34-1.52), and 1.11 (1.06-1.16), respectively, compared with never smokers. This association was also observed in individuals without CKD, but the risk was comparable between former smokers with smoking cessation ≥ 20 years and non-smokers, suggesting that a longer cessation is required in patients with CKD to offset the smoking-related adverse effects.

Conclusions: Among former smokers with CKD, the risk of ASCVD or mortality was substantially attenuated with less smoking load and a longer duration of smoking cessation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation 医学-泌尿学与肾脏学
CiteScore
10.10
自引率
4.90%
发文量
1431
审稿时长
1.7 months
期刊介绍: Nephrology Dialysis Transplantation (ndt) is the leading nephrology journal in Europe and renowned worldwide, devoted to original clinical and laboratory research in nephrology, dialysis and transplantation. ndt is an official journal of the [ERA-EDTA](http://www.era-edta.org/) (European Renal Association-European Dialysis and Transplant Association). Published monthly, the journal provides an essential resource for researchers and clinicians throughout the world. All research articles in this journal have undergone peer review. Print ISSN: 0931-0509.
期刊最新文献
CD38 ligation in sepsis promotes nicotinamide phosphoribosyltransferase-mediated IL-6 production in kidney stromal cells. Oral dysbiosis initiates periodontal disease in experimental kidney disease. Prophylactic 2-week Glecaprevir/Pibrentasvir in Hepatitis C positive to negative kidney transplantation. The uremic solute 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) may enhance eryptosis and increase erythrocyte osmotic fragility through potential activation of Piezo1. Long-term outcomes of IgA nephropathy in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1